INTRODUCTION {#s1}
============

Colorectal cancer (CRC) remains ones of the leading causes of cancer deaths worldwide. Currently, CRC is estimated to be the third most commonly diagnosed cancer (140,250) and the third leading cause of cancer deaths (50,630) in the USA \[[@R1]\], highlighting the need for the development of more effective and less toxic therapeutic agents. The traditional model of tumourigenesis has been based on the idea that every cell within the tumour population is capable of tumour initiation and propagation. However, in the last decade with the emergence of the cancer stem cell (CSCs) hypothesis, it is postulated that a small fraction of cells are capable of tumour initiation and propagation and their presence are associated with a more aggressive tumour type \[[@R2]--[@R8]\]. Colorectal CSCs are characterised by the expression of CD133 positive cells \[[@R2], [@R4]\] and increasingly other surface markers such as CD44, Lgr5, EpCAM have been included in this profile \[[@R9]--[@R17]\].

Since the early 1980s, aberrant expression of the epidermal growth factor receptor (EGFR) has been widely reported in a range of epithelial malignancies including colorectal cancer. As such the EGFR remains an important therapeutic target for therapy with anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab, which have been incorporated into treatment paradigms for patients with refractory metastatic CRC \[[@R18]--[@R22]\]. However, a major challenge is intrinsic drug-resistance and/or acquired-resistance following a short course of therapy in patients with CRC. Indeed, RAS mutations have served as an important negative predictive biomarker for the primary resistance to therapy with anti-EGFR mAbs in patients. In another study, the CD133 was found to be increased in CRCs that are hyper-activated by mutations in the RAS-RAF-MEK-ERK pathways (Kemper et al., 2012). However, not all patients with wild type *KRAS* respond to therapy with anti-EGFR mAbs \[[@R23], [@R24]\] and objective responses of up to 44% have been reported in mCRC patients with *KRAS* mutations treated with FOLFIRI plus cetuximab in other studies \[[@R25]\].

To our knowledge, there are currently no studies on the co-expression and prognostic value of the putative CSCs biomarkers CD44, CD133, the wtEGFR and its heterologous ligands, and the type III-EGFR mutant (i.e. EGFRvIII) in patients with mCRC. Therefore, in this study using specific antibodies, we investigated the prognostic value of the co-expression of CD44, CD133, EGFRvIII, wtEGFR, and EGFR ligands in tumour specimens from 70 mCRC patients. We also investigated the expression levels of CD44, CD133 in a large panel of CRC cell lines and their association with response to treatment with standard cytotoxic drugs and the EGFR inhibitors. Moreover, using CRC cells and their drug-resistant variants, we investigated the role of CD44 and CD133 in the development of acquired-resistance to the EGFR inhibitors.

RESULTS {#s2}
=======

Clinicopathological features {#s2_1}
----------------------------

Patient clinicopathological characteristics are summarised in Table [1](#T1){ref-type="table"}. The median patient follow-up time was 4 years. None of the patients had received radiotherapy or chemotherapy prior to surgery. Forty three patients received post-operative adjuvant chemotherapy. Patients with tumours of N2 stage were found to have a shorter overall survival (*P* = 0.004) and disease-free survival (*P* = 0.0003). No significant association was found between survival and the other prognostic factors (Table [1](#T1){ref-type="table"}).

###### Patient clinicopathological characteristics and their association with overall survival and disease free survival using Kaplan-Meier analysis and log-rank Chi-squared test in 70 metastatic colorectal cancer patients

  --------------------------------------------------------------------------------------------------------------------------
  Characteristics    *N*   OS in years\    95% CI         *P*-value\      DFS in months\   95% CI            *P*-value\
                           (mean ± SE)                    (*χ*^2^-test)   (mean ± SE)                        (*χ*^2^-test)
  ------------------ ----- --------------- -------------- --------------- ---------------- ----------------- ---------------
  **Age in years**                                                                                           

   ≤70               19    5.478 ± 0.527   4.446--6.511   NS              58.737 ± 8.250   42.567--74.907    NS

   \>70              51    5.785 ± 0.361   5.078--6.492                   81.460 ± 6.288   69.136--93.785    

  **Gender**                                                                                                 

   Male              40    5.930 ± 0.415   5.117--6.743   NS              78.636 ± 7.630   63.682--93.590    NS

   Female            30    5.476 ± 0.450   4.593--6.359                   75.558 ± 8.212   59.464--91.653    

  **Tumour Site**                                                                                            

   Right colon       35    5.600 ± 0.449   4.720--6.480   NS              78.968 ± 8.184   62.927--95.008    NS

   Left colon        35    5.843 ± 0.419   5.022--6.663                   77.017 ± 7.269   62.770--91.265    

  **T stage**                                                                                                

   T4                18    5.477 ± 0.695   4.116--6.839   NS              71.000 ± 9.247   52.876--89.124    NS

   \<T4              52    5.783 ± 0.342   5.113--6.453                   76.092 ± 6.519   63.315--88.868    

  **N stage**                                                                                                

   N2                41    3.971 ± 0.308   3.368--4.574   0.004           36.489 ± 4.702   27.273--45.706    0.0003

   \<N2              19    6.047 ± 0.329   5.401--6.693                   88.842 ± 5.839   77.397--100.286   

  **M stage**                                                                                                

   M0                62    5.832 ± 0.315   5.214--6.450   NS              79.917 ± 5.951   68.252--91.581    NS

   M1                8     4.208 ± 0.601   3.031--5.386                   45.429 ± 6.432   32.822--58.035    

  **LVI**                                                                                                    

   Absent            48    5.949 ± 0.349   5.265--6.632   NS              82.441 ± 6.933   68.851--96.030    NS

   Present           22    5.142 ± 0.568   4.029--6.255                   57.516 ± 6.191   45.381--69.650    

  **Grade**                                                                                                  

   G3                41    5.869 ± 0.464   4.960--6.779   NS              74.818 ± 7.324   60.463--89.173    NS

   \<G3              29    5.592 ± 0.408   4.792--6.392                   79.061 ± 8.776   61.860--96.262    

  **Chemotherapy**                                                                                           

   No                17    5.250 ± 0.618   4.040--6.460   NS              58.063 ± 8.071   42.244--73.881    NS

   Yes               43    6.012 ± 0.450   5.257--6.766                   80.511 ± 6.888   67.010--94.011    
  --------------------------------------------------------------------------------------------------------------------------

Immunohistochemical expression of CD44, CD133, EGFRvIII, wtEGFR and ligands in colorectal tumors {#s2_2}
------------------------------------------------------------------------------------------------

The expression of CD44 and CD133 was determined in all 70 Dukes' C and D colorectal cases by immunohistochemistry. The pattern of CD44 immunostaining was found to be membranous and low and high expression in 83% and 17% of the patients respectively (Figure [1A](#F1){ref-type="fig"} and Table [2A](#T2){ref-type="table"}). CD133 was found to stain the luminal border with immunostaining present in necrotic debris in well differentiated tumours and a dot-like staining in poorly differentiated tumours with 23% and 77% of the cases expressing high and low levels of CD133 staining (Figure [1B](#F1){ref-type="fig"} and Table [2A](#T2){ref-type="table"}).

![Immunohistochemical staining of the metastatic colorectal cancer specimens for CD44 and CD133 expression showing the intensity of staining (**A**), and the cellular location of staining (**B**).](oncotarget-10-1704-g001){#F1}

###### Immunohistochemical expression of (A) CD44, CD133, (B) wtEGFR, EGFRvIII and EGFR ligands and their co-expressions in 70 metastatic colorectal cancer patients

  A                                               
  ----------- --------- --------- ---------- ---- ----------
  **CD44**    58 (83)   12 (17)   70 (100)   \-   \-
  **CD133**   54 (77)   16 (23)   \-         \-   70 (100)

Abbreviations: Mem, Membranous; Cyt, Cytoplasmic.

  B                                                                                                            
  ------------------------------ --------- --------- --------- --------- --------- --------- ------- --------- ---------
  **wtEGFR**                     18 (26)   12 (17)   9 (13)    4 (6)     15 (21)   2 (3)     1 (1)   17 (24)   2 (3)
  **EGFRvIII**                   9 (13)    5 (7)     4 (6)     4 (6)     9 (13)    \-        \-      \-        9 (13)
  **Amphiregulin**               35 (50)   4 (6)     11 (16)   20 (29)   26 (37)   14 (20)   \-      \-        35 (50)
  **BTC**                        53 (76)   3 (4)     14 (20)   40 (57)   45 (64)   25 (36)   \-      \-        53 (76)
  **EGF**                        49 (70)   6 (9)     5 (7)     34 (49)   36 (51)   25 (36)   \-      \-        49 (70)
  **TGFα**                       51 (73)   2 (3)     7 (10)    39 (56)   47 (67)   4 (6)     \-      \-        51 (73)
  **wtEGFR/1 ligand**            11 (16)   \-        \-        \-        \-        \-        \-      \-        \-
  **wtEGFR/1 or more ligands**   17 (24)   \-        \-        \-        \-        \-        \-      \-        \-
  **Any CSC/wtEGFR**             6 (9)     \-        \-        \-        \-        \-        \-      \-        \-
  **Any CSC/EGFRvIII**           2 (3)     \-        \-        \-        \-        \-        \-      \-        \-

Abbreviations: Mem, Membranous; Cyt, Cytoplasmic.

At cut-off value of \>5%, wtEGFR expression was membranous in 26%, while EGFRvIII expression was observed predominantly in cytoplasm in 13% of the colorectal patients (Figure [2A](#F2){ref-type="fig"} and Table [2B](#T2){ref-type="table"}). Of the EGFR ligands, amphiregulin, BTC, EGF, and TGFα were expressed in the cytoplasm of 50%, 76%, 70%, and 73% of the tumours respectively (Figure [2A](#F2){ref-type="fig"} and Table [2B](#T2){ref-type="table"}). Immunohistochemical expression of epiregulin, HBEGF, and epigen were undetectable in this study.

![Immunohistochemical expression of wtEGFR, EGFRvIII, and EGFR ligands (**A**), association between the expression of wtEGFR, amphiregulin and BTC and survival shown with Kaplan Meier curves (**B**) in 70 metastatic colorectal cancer patients.](oncotarget-10-1704-g002){#F2}

Of the 70 CRC patients examined, 36% expressed at least one of the CSC markers (CD44 or CD133). However, the co-expression of CD44 or CD133 with EGFRvIII and wtEGFR was found in only 3% and 9%, respectively. At cut-off value \>5%, 17/70 patients were found to co-express wtEGFR with at least one ligand while 11/70 patients co-expressed wtEGFR with all 4 ligands (Table [2B](#T2){ref-type="table"}).

CD133, EGF and TGFα expression is significantly associated with clinicopathological parameters {#s2_3}
----------------------------------------------------------------------------------------------

The expression of CSCs, EGFRvIII, wtEGFR and its ligands was analysed against clinicopathological characteristics of patients using Chi-squared and Fisher Exact tests. A significant association was found between the expression of CD133^H^ and tumours with \<G3 differentiation (*P* = 0.019). At cut-off value \>50%, the expression of TGFα was also significantly associated with tumours \<G3 (*P* = 0.028). Interestingly, EGF expression above a cut-off value of 50% was significantly associated with M1 stage (*P* = 0.002).

EGFRvIII, amphiregulin, and BTC is significantly associated with survival {#s2_4}
-------------------------------------------------------------------------

A significant association was found between EGFRvIII (*P* = 0.005) and amphiregulin (*P* = 0.017) expressions at cut-off value of \>50% and shorter overall survival (Figure [2B](#F2){ref-type="fig"}). Univariate analysis found a 4.5 fold and 2 fold increased risk of a shorter overall survival with expression of EGFRvIII (*P* = 0.016) and amphiregulin (*P* = 0.04), respectively and remained independent prognostic indicators of survival when analysed in multivariate analysis in this study (Table [3](#T3){ref-type="table"}).

###### The association of expression of EGFRvIII, amphiregulin with overall survival (OS) and BTC with disease-free survival in 70 metastatic colorectal cancer patients using multivariate Cox regression analysis

  Overall Survival (OS)                                                                                          
  --------------------------------- ---------------- ------------------ --------- ------------ ----------------- ---------
  **EGFRvIII**                      4.568            1.325--15.748      *0.016*   7.215        1.941--26.817     *0.003*
  **Amphiregulin**                  2.070            1.035--4.139       *0.04*    2.082        1.040--4.167      *0.038*
  **Disease-free Survival (DFS)**                                                                                
  **Variables**                     **Univariate**   **Multivariate**                                            
  **HR**                            **95% CI**       ***P*-*value***    **HR**    **95% CI**   ***P*-*value***   
  **BTC**                           0.375            0.153--0.920       *0.032*   0.369        0.150--0.910      *0.030*

*P*-value of ≤0.05 was considered significant.

The expression of BTC at cut-off value of \>50% was found to be significantly associated with longer disease-free survival (*P* = 0.025) (Figure [2B](#F2){ref-type="fig"}) and multivariable analyses showed that BTC expression was an independent prognostic indicator of favourable disease-free survival (HR = 0.369, CI = 0.150 -- 0.910, *P* = 0.03) in these patients (Figure [2B](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}).

Interestingly, the co-expression of CD44 or CD133 with EGFRvIII was significantly associated with shorter overall survival (*P* = 0.037) and remained an independent prognostic indicator of overall survival when adjusted for multivariable effect (HR = 5.451, CI = 1.193 -- 24.906, *P* = 0.029) (Table [3](#T3){ref-type="table"}).

CD44 and CD133 expression in human colorectal tumor cell lines {#s2_5}
--------------------------------------------------------------

The cell surface expression of CD44 and CD133 was determined by flow cytometry in reference to positive control cell lines (Figure [3A](#F3){ref-type="fig"}). Of the human colorectal tumour cell lines examined in this study, HCT116, HT29, CCL-228 and DiFi cells were highly CD44 positive (i.e. \>95% of tumour cell populations), while CCL-225 and Colo-2 cells were CD44 negative (Figure [3A](#F3){ref-type="fig"}). CD133 positive cell population was much lower in the majority of colorectal tumour cells, with only CaCo-2 cells expressing CD133 in more than 95% of the cells (Figure [3A](#F3){ref-type="fig"}).

![Expression of CD44 and CD133 in human colorectal tumour cell lines (**A**), association between CD133 expression and treatment with irinotecan (**B**), expression of CD44 and CD133 in DiFi parental versus DiFi62 and DiFiG acquired resistant variant cells (**C**), ±SD determined by flow cytometery (*n* = 3).](oncotarget-10-1704-g003){#F3}

Association between expression of CD44 and CD133 and response to treatment with cytotoxic drugs {#s2_6}
-----------------------------------------------------------------------------------------------

We have reported previously the growth response of human colorectal tumour cell lines to treatment with anti-EGFR mAb ICR62 and cytotoxic drugs \[[@R26]\]. Of the cell lines examined, only the EGFR overexpressing DiFi cells were highly sensitive to treatment with anti-EGFR mAb ICR62. We found no significant association between the expression of CD44 and/or CD133 and response to treatment with anti-EGFR mAb ICR62, irreversible ErbB inhibitor afatinib, and reversible ErbB inhibitors erlotinib and gefitinib (data not shown). Of the cytotoxic drugs, no significant association was found between the expression of CD44 and/or CD133 and response to treatment with 5FU or Oxaliplatin. Interestingly, there was a significant association between the expression of CD133, and its co-expression with CD44 and resistance to treatment with irinotecan (Figure [3B](#F3){ref-type="fig"}).

We reported previously development of the EGFR overexpressing DiFi cell variants with acquired resistance to the anti-EGFR mAb ICR62, and TKI gefitinib \[[@R27]\]. Interestingly, we found the expression of CD44 to be significantly increased in both resistant variants DiFi62 and DiFiG cells (Figure [3C](#F3){ref-type="fig"}). CD133 expression, on the other hand was significantly increased only in DiFiG cells.

DISCUSSION {#s3}
==========

CSC are characterised by slow proliferation and cell cycle and as such have been associated with resistance to anticancer therapies through the deployment of various defence mechanisms such as activation of anti-apoptotic proteins, efflux pumps, and quiescence \[[@R28]\]. Because conventional chemotherapies target rapidly growing cells, initial treatment response in the form of tumour shrinkage is seen but they fail to eradicate the cancer as the tumour initiating CSCs are spared.

In this study, we have evaluated the association between the co-expression of putative CSC markers CD44, CD133, which have been shown to identify cells with tumour initiating and progression properties \[[@R3]--[@R7], [@R29]\]. Our findings suggest that despite putative CSC markers CD44 and CD133 being expressed commonly and the expression of CD133 being associated significantly with well and moderately differentiated tumours, there was no significant association with patient outcome in this study. Indeed, the prognostic significance of CD44 and CD133 in patients with CRC has been investigated in several studies \[[@R11], [@R30]--[@R33]\]. However, to our knowledge only four studies have investigated the combined expression and prognostic significance of both CD44 and CD133 in CRC patients using IHC and found contradicting results. Horst and colleagues investigated the expression of CD44, CD133 and CD166 in 110 CRC patient tumours by IHC and found 33%, 52% and 64% of the cases positive respectively. The co-expression of all three markers was found in 36% of the cases and concluded CD133 to be the best sole marker to predict low patient survival \[[@R32]\]. Another study, which investigated the expression of CD24, CD44 and CD133 in 523 tissue microarrays from CRC patients by IHC, found CD24, CD44 and CD133 expression in 51%, 96% and 25% of the cases examined respectively. Although the study found CD133 expression to be associated with gender and advance T-stage, no significant association was found between expression of CD44 and CD133 and survival \[[@R30]\]. Furthermore, Lugli and colleagues using TMA evaluated 1420 primary CRC and 57 normal mucosa samples for the expression of CD133, CD44s, CD166, EpCAM, and ALDH1 but failed to find any association between expression of these markers and patient outcome \[[@R34]\]. More recently, another study conducted by Jing *et al.* (2015) examined 36 colorectal primary adenocarcinomas with synchronous hepatic metastasis and found CD44, but not CD133, expression was independent factor associated with survival \[[@R35]\]. Finally, the results of two recent meta-analyses of 65 studies have also indicated that the high expression of CD133 is associated with poorer 5year overall survival and disease-free survival highlighting that CD133 could serve as a predictive biomarker of poor prognosis and treatment failure as well as a potential therapeutic target in patients with mCRC \[[@R36], [@R37]\].

One of the findings of the present study was that the co-expression of CSCs and EGFRvIII was found to be an independent factor associated with worse overall survival, albeit in a small number of patients. EGFRvIII is a ligand-independent, mutated form of the EGFR and its expression has been associated with poor prognosis in several human cancers \[[@R38]--[@R40]\]. To our knowledge, there have been no other studies on the co-expression of CSCs and EGFRvIII, wtEGFR and its ligands in patients with mCRC and as such this is a novel finding and warrants further investigation in a larger cohort of mCRC patients. The aberrant expression of EGFR and its ligands have been associated with poor outcome to therapy in various human malignancies, including CRC \[[@R38], [@R41]--[@R44]\]. In the present study while we did not find any association between the wtEGFR expression and survival, expression of amphiregulin was found to be a significant independent factor for poorer overall survival in these patients, which was consistent with the findings of other studies \[[@R45]--[@R49]\]. Interestingly, we found BTC expression to be a significantly associated with a favourable outcome in patients with mCRC. However, more recently, another study conducted by Yun *et al.* that examined 331 CRC for the association between the expression of EGFR family members and its ligands. While the study did not find any association between BTC expression and overall survival, they found the expression of HER4, another member of the EGFR family, to have a favourable outcome in patients with CRC \[[@R41]\]. BTC is known to also bind to HER4, which has been shown to be associated with better outcome in some cancers, including breast and gastric \[[@R50]--[@R52]\]. Indeed, the expression of HER4 although not determined in the present study, was determined in our previous study on the same cohort of patients with high expressions of HER4 (data not shown) \[[@R53]\]. This could, in part, provide an explanation for the association of BTC expression interacting with the overexpressed HER4 in these patients and contributing to a longer disease-free survival in the present study.

Nautiyal *et al.* investigated EGFR regulation of colon cancer stem-like cells (CD44, CD166 and ALDH-1 positive cells) and found EGFR inhibition by anti-EGFR mAb cetuximab diminished age-related increase of CD166 and ALDH-1 suggesting EGFR could have an important role in the regulation of colorectal CSC \[[@R54]\]. In this study, for the first time we investigated the expression of CD44 and CD133 in a large panel of human colorectal tumour cell lines and determine association to sensitivity to treatment with anti-HER inhibitors and cytotoxic drugs. We found that CD44 expression is more common than CD133 expression in human colorectal tumour cell lines and patient samples. While we did not find any significant association between expression of CD44 and/or CD133 and response to anti-EGFR mAb ICR62, and irreversible erbB inhibitor afatinib, reversible small molecule tyrosine kinase inhibitors erlotinib and gefitinib (data not shown), there was a significant association between CD133 expression and its co-expression with CD44 and response to treatment with the cytotoxic drug irinotecan. These findings are in line with previous studies of other cancer types where the expression of CSCs were found to be associated with radio- and/or chemo-resistance in cancers of prostate, hepatocellular and breast \[[@R55]--[@R58]\]. In addition, we have also observed a significant increase in the expression of CD44 and CD133 in CRC tumour cells with acquired resistance to anti-EGFR mAb and TKI therapies further highlighting the role played by CSCs not only in primary drug resistance, but also in the development of acquired drug resistance. However, further studies are warranted and should confirm the possible link between expressions of CSCs and response to treatment with the EGFR inhibitors.

In conclusion, our results suggest that co-expression of CSCs and EGFRvIII and the expression of amphiregulin are associated with poorer overall survival in patients with mCRC. However, expression of other ligands such as BTC, through its interactions with other EGFR family members such as HER4, could contribute to a longer disease-free survival in some mCRC patients. Since colorectal cancer was predicted to be the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide in 2018 \[[@R59]\], our results support the need for further studies and its validation on the prognostic significance of the co-expression of CSCs, EGFRvIII, and the wtEGFR and its ligand and their predictive value for the response to therapeutic interventions in a larger group of patients with mCRC.

MATERIALS AND METHODS {#s4}
=====================

Tumor cell lines {#s4_1}
----------------

The human colorectal tumour cell lines CCL-221 (Dukes' C), CCL-225 (Dukes' C), CCL-228 (Dukes' B), CCL-244 (tumour stage unknown) and CCL-235 (Dukes' D), CaCo-2 were purchased from the American Type Culture Collection (Manassas, VA) and HCT-116 (tumour stage unknown), HT-29 from European Collection of Cell Culture (Porton Down, United Kingdom). Other human colorectal tumour cell lines used in this study included our two cell lines Colo-2 (Dukes' A) and Colo-13 (Dukes' C) \[[@R60]\] and the EGFR over-expressing cell line DiFi which was established from a patient with familial adenomatous polyposis (FAP) and was kindly provided by Dr Z Fan (MD-Anderson Cancer Centre). Acquired drug resistant variants of DiFi cells were developed as described previously \[[@R27]\]. All cell lines were routinely cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) (Merck, Gillingham, UK) supplemented with 10% foetal bovine serum (FBS) (Merck, UK) and the antibiotics penicillin, streptomycin and neomycin and were maintained at 37°C in a humidified atmosphere with 5% CO~2~.

Antibodies, EGFR inhibitors and other reagents {#s4_2}
----------------------------------------------

The rat monoclonal antibody ICR62 (IgG~2b~) was raised against the external domain of the EGFR on the breast carcinoma cell line (MDA-MB468) \[[@R61]\]. The secondary antibody used in this study included FITC-conjugated rabbit anti-mouse IgG Star 9B (Bio-rad Antibodies, Kidlington, UK). The cytotoxic drugs, 5-FU, Irinotecan and Oxaliplatin were purchased from Merck, UK.

Flow cytometry {#s4_3}
--------------

The cell surface expression level of CSC markers CD44 and CD133 in human colorectal tumour cell lines and drug resistant variants was determined using FACScalibur, employed for the determination of EGFR family members (Becton Dickinson, Oxford, UK) as described previously \[[@R26]\].

Patient information {#s4_4}
-------------------

Seventy patients with metastatic CRC (Dukes' C and D) who underwent radical surgery at the Royal Surrey County Hospital (Guildford, UK) between April 2002 and November 2007 were included in this retrospective study. Ethical approval was obtained from the Research and Development Committee of the Royal Surrey County Hospital. Those with no follow-up information, mis-diagnosis, and incomplete histology were excluded. Cases of peri- and post-operative death (i.e. within 6 months of surgery) were also excluded from this study, as were those with tumour blocks in a condition too poor for immunohistochemical use. Detailed clinicopathological information, including patient age and gender was available for each patient.

Immunohistochemistry {#s4_5}
--------------------

Paraffin-embedded sections of tumour specimens (3 μM) and control cell pellets (Caco-2) were cut from paraffin-embedded blocks. IHC staining was carried out as described previously \[[@R53]\], using the following primary antibodies: mouse anti-wild-type EGFR (M7298) and mouse anti-human CD44 mAb (M7082) (Agilent, Stockport, UK), anti-EGFRvIII (BS-2558R), rabbit pAb anti-Amphiregulin (GTX100986, InsightBiotech, London, UK), mouse anti-EGF (AHP767), mouse anti-TGFα (AHP284G) (Bio-Rad Antibodies, UK), mouse anti-Betacellulin (MAB2611) (Biotechne, Abingdon, UK), rabbit pAb anti-HBEGF (HPA053243), rabbit pAb anti-Epigen (HPA014420), and rabbit pAb anti-Epiregulin (HPA054373) (Merck, UK), and mouse anti-human CD133 (130-090-422) (Miltenyi Biotec, Surrey, UK).

Scoring criteria {#s4_6}
----------------

The immunostaining of the tumour sections were scored based on the percentage of tumour cells that had EGFR and/or ligands immunostaining (i.e. \>5%, \>10%, \>20%, and \>50%) and intensity of immunostaining (i.e. negative 0, weak 1+, moderate 2+ and strong 3+) and location (i.e. membrane, cytoplasm or nucleus of the cells). CD44 and CD133 sections were scored by the percentage of positive cells (0% to 50% and ≥50%) as low (^L^) and high (^H^), respectively. The immunostaining was scored by two independent observers without prior knowledge of the clinicopathological parameters and any disparity in scoring was resolved by simultaneous reassessment of the staining by both observers.

Statistical analysis {#s4_7}
--------------------

The relationship between the expression levels of CSCs and response to treatment was determined by linear regression analysis and changes in the expression of CSCs in drug resistant variants were tested by Paired *T*-test analysis. The association between immunohistochemistry scores and patient clinicopathological data was assessed using Chi-Squared test (Pearson Chi-Square) and Fisher Exact Test. Kaplan-Meier survival plots were used to evaluate differences between groups by performing log rank-test. For univariate and multivariate analysis, the Cox regression model was used and *P* ≤ 0.05 was considered statistically significant. All statistical analyses were carried out using the PASW statistics 24 (SPPS Inc.).
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